Introduction {#section1-1533033818793425}
============

Breast cancer is the most common cancer and the leading cause of cancer-related deaths in females all around the world. Researchers calculated that there was an estimated 1.7 million breast cancer and 521 900 deaths every year.^[@bibr1-1533033818793425]^ In the United States, ductal carcinoma in situ (DCIS) accounts for more than 20% of all breast cancer types. The recurrence rate of DCIS is 26% to 36% (without radiotherapy) or 9% to 23% (radiotherapy), and half of the recurrence of cancers are invasive.^[@bibr2-1533033818793425]^ Surgery remains the mainstream method for early-stage breast cancer, but prognosis depends on its invasiveness and metastasis. In recent years, the radiotherapy, chemotherapy, and biotherapy have been used more and more in tumorous comprehensive therapy.^[@bibr3-1533033818793425],[@bibr4-1533033818793425]^ For those cases undergoing breast-preserving surgery or with high risk of recurrence, radiotherapy can significantly reduce the recurrence rate. However, a certain percentage of these patients still have breast cancer recurrence after radiotherapy.

Radiotherapy is the common means for the treatment of malignant tumors. A growing number of research revealed that radiotherapy was closely related to tumor immunity.^[@bibr5-1533033818793425][@bibr6-1533033818793425]-[@bibr7-1533033818793425]^ In the course of radiation therapy, the body's immune system was inevitably accepted to a certain extent radiation, resulting in damage to immune cells. In addition, bone marrow tissue was highly sensitive to radiation and easily been suppressed. The origin of bone marrow cells generation reduced, including the original immune cell. However, recent studies found that the hypolymphemia caused by radiotherapy followed by rapid proliferation of immune cells for restoring immunity homeostasis. The phenomenon of killing and regeneration was benefit to eliminate invalid T cells. Proliferated cells had the characteristics of memory cells and effector cells, which was beneficial to the enhancement of antitumor effect. Another experiment showed that low-dose radiation had immune-promoting effect by reducing the proportion and number of Treg cells.

The immune response of tumor microenvironment determines the biological behavior of tumor cells. Immune system plays a protective role through eliminating or inhibiting the tumor cells. Recently, researches indicated that the damagement of immune microenvironment had a negative effect on radiotherapy in various tumors.^[@bibr8-1533033818793425][@bibr9-1533033818793425][@bibr10-1533033818793425]-[@bibr11-1533033818793425]^ Programmed cell death protein-1 (PD-1) plays an important role in tumor immunity. Cancer cells escape immune attack by upregulating the expression of PD-1, which combined with PD-L1 and restricted host immune response. Study revealed that PD-1 shortened the survival of melanoma-bearing mice treated with radiotherapy. However, PD-1 blocking antibody led to an opposite tendency in further experiment. And the combination of stereotactic ablative radiotherapy plus PD-1 blockade induced almost complete retrogression of the irradiated primary tumor, which was famous as synergistic effect.^[@bibr12-1533033818793425]^ However, the role of PD-1 in recurrence of breast cancer subjected to radiotherapy is unknown. In this study, a retrospective analysis was designed to explore the relevance.

Materials and Methods {#section2-1533033818793425}
=====================

Patient Data {#section3-1533033818793425}
------------

The retrospective study included 42 patients with breast cancer from January 2012 to June 2017 in our department, whose diagnosis was confirmed by surgery and pathology. The total 42 cases contained 18 recurrent cases and 24 recurrence-free cases. The inclusion criteria in the study were as follows: (1) newly diagnosed, unilateral breast cancer, and underwent surgery. (2) Accepted postoperative radiotherapy, 5 times a week and 2 Gy every time. Carry out the radiation dose of 50 Gy and append 10 Gy to tumor bed. (3) Availability of at least 1 block of formalin-fixed and paraffin-embedded tumor tissue containing viable breast cancer tissue, used for immunohistochemistry (IHC). (4) Availability of full clinical follow-up data, no prior chemotherapy or radiotherapy before surgery. We followed up for 5 years and the median follow-up time was 62 months. The clinical data of age, gender, tumor location, tumor size, histological type, and TNM stage were collected. The study was approved by the ethics committee of The Affiliated Jiangning Hospital of Nanjing Medical University (\#20170302), and informed consent was obtained from all patients and volunteers.

Immunohistochemistry Analysis {#section4-1533033818793425}
-----------------------------

The tissue sections from available tumors were collected for IHC. Four-micrometer sections were cut and mounted on SuperFrost Plus electrostatically charged glass slides with the help of pathology department. Sections were dried overnight in a 37°C incubator followed by PD-1 staining. The sections were treated lightly according to the instructions of immunostain streptavidin--peroxidase and SP kit before incubation of antibody. For PD-1 staining, the slides were incubated with a monoclonal rabbit anti-PD-1 antibody (Cell Signaling Technology, Massachusetts, USA) applied at a 1/200 dilution and detected with the UltraView Universal DAB Detection Kit. All slides were counterstained for 4 minutes with hematoxylin followed by a 4-minute incubation with Bluing Reagent. The stained sections were dehydrated, and glass coverslips were mounted. The PD-1 expression of tumor-infiltrating lymphocytes (TILs) on IHC-stained tissues was independently performed by 2 trained pathologists who were blinded to the clinical and experimental data. The expression of PD-1 was assessed as a continuous variable based on the percentage of tissue area occupied by PD-1 positive T cells. Discordant results were jointly reevaluated by the pathologists.

T Lymphocyte Subsets Detection {#section5-1533033818793425}
------------------------------

T lymphocyte subsets (CD3^+^, CD4^+^, CD8^+^, and natural killer \[NK\]) of peripheral blood were detected in patients and 20 health people who took physical examination by laboratory. Those subsets determined before and after postoperative radiotherapy when at the time of the primary treatment. Before radiotherapy, 1 week after radiotherapy and 3 weeks after radiotherapy were detection time point, respectively.

Statistical Analysis {#section6-1533033818793425}
--------------------

All statistical analyses were performed using SPSS software (IBM SPSS Statistics for Macintosh version 20.0). The Student *t* test and the χ^2^ test were used to evaluate statistical differences of PD-1 expression in different samples and examine the relationship between PD-1 expression and clinicopathological features. The recurrence-free survival of patient was estimated using the Kaplan-Meier method. In all cases, *P* \< .05 was considered statistically significant.

Results {#section7-1533033818793425}
=======

Correlation of PD-1 Expression With Clinicopathological Features {#section8-1533033818793425}
----------------------------------------------------------------

The clinical characteristics of patients and grouping were summarized in [Table 1](#table1-1533033818793425){ref-type="table"}. A total of 24 recurrence-free and 18 recurrence female patients were enrolled. All these patients were at an early stage of breast cancer (8 stage I and 34 stage II according to TNM stage). The PD-1 was detected, and the median expression level was used to separate the patients into 2 subgroups (low-expression group \[n = 21\] and high-expression group \[n = 21\]). We found recrudesce was obviously associated with the expression of PD-1 in TILs (*P* = .013). There was no difference between PD-1 and other clinicopathological characteristics, such as age, TNM stage, and differentiation ([Table 2](#table2-1533033818793425){ref-type="table"}).

###### 

Patient Characteristics.

![](10.1177_1533033818793425-table1)

  Feather             RFG   RG   *P* Value
  ------------------- ----- ---- -----------
  Total cases                    
   42                 24    18   \-
  Gender                         
   Male               0     0    \-
   Female             24    18   \-
  Age                            
   ≤35                7     5    .921
   \>35               17    13   
  TNM stage                      
   I                  4     4    .955
   II                 20    14   
  Differentiation                
   Well               4     3    1.000
   Moderate           17    13   .921
   Poorly             3     2    1.000
  Herceptin                      
   Yes                8     5    .700
   No                 16    13   
  Endocrine therapy              
   Yes                15    10   .650
   No                 9     8    
  PD-1                           
   Low                16    5    .013\*
   High               8     13   

Abbreviations: PD-1, programmed cell death protein-1; RFG, recurrence-free group; RG, recurrence group.

###### 

Correlation Between PD-1 and Clinicopathological Characteristics.

![](10.1177_1533033818793425-table2)

  Feather             PD-1 Low   PD-1 High   *P* Value
  ------------------- ---------- ----------- -----------
  Total cases                                
   42                 21         21          \-
  Gender                                     
   Male               0          0           \-
   Female             21         21          
  Age                                        
   ≤35                5          7           .495
   \>35               16         14          
  TNM stage                                  
   I                  5          3           .694
   II                 16         18          
  Differentiation                            
   Well               5          2           .408
   Moderate           15         15          1.000
   Poorly             1          4           0.341
  Herceptin                                  
   Yes                8          5           .317
   No                 13         16          
  Endocrine therapy                          
   Yes                15         10          .116
   No                 6          11          

Abbreviation: PD-1, programmed cell death protein-1.

Association of PD-1 Expression and Recurrence-Free Survival {#section9-1533033818793425}
-----------------------------------------------------------

Mean follow-up time was 62 months. The recurrence-free mean survival in PD-1 low-expression group was 68 months, and the recurrence-free mean survival in PD-1 high-expression group was 56 months. Recurrence and June 2017 acted as the end of the follow-up. As shown in [Figure 1](#fig1-1533033818793425){ref-type="fig"}, Kaplan-Meier curves showed that the recurrence-free survival was significantly longer in PD-1 low-expression group than that in PD-1 high-expression group.

![Recurrence-free survival. Kaplan-Meier curves showing recurrence-free mean survival time of programmed cell death protein-1 (PD-1) low-expression group and PD-1 high-expression group.](10.1177_1533033818793425-fig1){#fig1-1533033818793425}

Association of T-Lymphocyte Subsets and PD-1 Expression {#section10-1533033818793425}
-------------------------------------------------------

The levels of CD4^+^ and CD4^+^/CD8^+^ were obviously lower in patients with breast cancer than healthy group (*P* \< .05; [Table 3](#table3-1533033818793425){ref-type="table"}). On the contrary, the NK expression was higher (*P* \< .05). CD4^+^ decreased significantly after 1 week's radiotherapy and recovered rapidly 3 weeks after radiotherapy. Compared to that in recurrence-free group (RFG), the expression of CD4^+^ was lower in the recurrence group (RG) both at 1 week after radiotherapy point and 3 weeks after radiotherapy point (*P* \< .05). The increments in most T lymphocytes were significantly lower (*P* \< .05) in RG than that in RFG. Compared to that in PD-1 low group, the expression of CD4^+^ was lower PD-1 high group both at 1 week after radiotherapy point and 3 weeks after radiotherapy point (*P* \< .05; [Table 4](#table4-1533033818793425){ref-type="table"}). The increments of CD4^+^ were significantly lower (*P* \< .05) in PD-1 high group than that in PD-1 low group.

###### 

Correlation Between T Lymphocyte Subsets and Radiotherapy.^a^

![](10.1177_1533033818793425-table3)

  Groups                      CD3^+^          CD4^+^               CD8^+^          CD4^+^/CD8^+^      NK
  --------------------------- --------------- -------------------- --------------- ------------------ -----------------
  HG                          72.2 ± 4.4      53.7 ± 2.3           33.2 ± 3.5      1.62 ± 0.21        8.1 ± 2.6
  Before radiotherapy                                                                                 
   RFG                        68.9 ± 4.2      43.5 ± 1.9^b^        32.5 ± 3.2      1.34 ± 0.12^b^     11.9 ± 3.4^b^
   RG                         67.8 ± 3.6      41.1 ± 2.2^b^        35.9 ± 4.3      1.14 ± 0.19^b^     12.1 ± 2.9^b^
  1 week after radiotherapy                                                                           
   RFG                        66.6 ± 5.2      38.7 ± 1.8 ^b,c^     35.6 ± 5.6      1.08 ± 0.25^b,c^   9.8 ± 2.1
   RG                         65.3 ± 4.7^b^   35.9 ± 3.6 ^b,c,e^   37.1 ± 4.8^b^   0.96 ± 0.24^b^     9.3 ± 3.2
  3 week after radiotherapy                                                                           
   RFG                        66.9 ± 3.9      43.3 ± 2.8^b,d^      33.7 ± 4.3      1.28 ± 0.22^b^     10.8 ± 4.9
   RG                         66.1 ± 4.6^b^   39.2 ± 4.1^b,d,e^    36.3 ± 3.9^b^   1.07 ± 0.23^b,e^   11.7 ± 4.8^b,d^

Abbreviations: HG, healthy group; NK, natural killer; RFG, recurrence-free group; RG, recurrence group.

^a^ Results are expressed as the means ± SEM.

^b^ *P* \< .05 versus HG.

^c^ *P* \< .05 versus before radiotherapy.

^d^ *P* \< .5 versus 1 week after radiotherapy;

^e^ *P* \< .05 versus RFG.

###### 

Correlation Between PD-1 and T Lymphocyte Subsets When Receiving Radiotherapy.^a^

![](10.1177_1533033818793425-table4)

  Groups                      CD3^+^          CD4^+^              CD8^+^          CD4^+^/CD8^+^      NK
  --------------------------- --------------- ------------------- --------------- ------------------ -----------------
  HG                          72.2 ± 4.4      53.7 ± 2.3          33.2 ± 3.5      1.62 ± 0.21        8.1 ± 2.6
  Before radiotherapy                                                                                
   PD-1^low^                  66.2 ± 2.2      43.2 ± 1.7^b^       33.0 ± 3.3      1.31 ± 0.14^b^     11.5 ± 2.4^b^
   PD-1^high^                 69.7 ± 4.6      41.6 ± 2.1^b^       35.2 ± 4.4      1.18 ± 0.20^b^     12.6 ± 2.9^b^
  1 week after radiotherapy                                                                          
   PD-1^low^                  65.5 ± 4.4^b^   38.4 ± 2.2^b,c^     36.0 ± 5.8^b^   1.01 ± 0.26^b,c^   10.2 ± 3.1
   PD-1^high^                 66.6 ± 5.1      36.4 ± 3.2^b,c,e^   36.5 ± 5.0^b^   1.00 ± 0.22^b^     8.7 ± 3.2
  3 week after radiotherapy                                                                          
   PD-1^low^                  65.8 ± 3.5^b^   44.1 ± 2.7^b,d^     34.0 ± 4.5      1.30 ± 0.19^b,d^   10.4 ± 3.9
   PD-1^high^                 67.5 ± 4.2      39.5 ± 4.2^b,d,e^   35.8 ± 3.7^b^   1.10 ± 0.25^b,e^   12.1 ± 2.8^b,d^

Abbreviations: HG, healthy group; NK, natural killer; PD-1, programmed cell death protein-1; RFG, recurrence-free group.

^a^ Results are expressed as the means ± SEM.

^b^ *P* \< .05 versus HG.

^c^ *P* \< .05 versus before radiotherapy.

^d^ *P* \< .5 versus 1 week after radiotherapy.

^e^ *P* \< .05 versus RFG.

Discussion {#section11-1533033818793425}
==========

According to statistical information, the incidence of breast cancer in women in China was increasing year by year, and the mortality rate was the second. Surgical resection is the most direct and effective treatment of breast cancer. With people's attention to their appearance, more and more patients choose breast-preserving surgery, especially in early stage. To further remove residual lesions, radiotherapy was an effective treatment and was applied in most patients.

A growing number of researches have revealed that radiotherapy could reduce the postoperative recurrence and improve prognosis in various cancers, including colorectal cancer, breast cancer, prostate cancer, and esophagus cancer.^[@bibr5-1533033818793425],[@bibr13-1533033818793425]^ Postoperative breast irradiation was considered as standard after breast-preserving surgery for cancer.^[@bibr14-1533033818793425]^ A 15-year follow-up study found that approximately 1 in 3 nonirradiated patients developed a local recurrence after breast-preserving excision for DCIS. However, adjuvant radiation therapy significantly reduced this risk.^[@bibr15-1533033818793425]^ But, there were a part of women subjected to tumor recurrence after adjuvant radiation therapy and decreased survival quality.

It is generally known that immune system plays an important role in antitumor activity and immunocompromised subjects respond with lower response rate to treatment. In this study, a critical immune molecule PD-1 was detected to explore the role in recurrence of patients undergoing breast-preserving surgery and radiotherapy. This study demonstrated that the expression of PD-1 was significantly correlated with breast cancer recurrence. Kaplan-Meier curve analysis revealed that the recurrence-free mean survival was significantly longer in PD-1 low-expression group (68 months) than that in PD-1 high-expression group (56 months). Because overexpression of PD-1 could restrict host immune response and induce immune evasion of cancer cells, the rate of recurrence became higher. PD-1 may be a new therapeutic target for prevention of recurrence. In preclinical models of bladder cancer, study demonstrated anti-PD-1 or anti-PD-L1 antibodies could enhance radiotherapy-induced antitumor immunity.^[@bibr16-1533033818793425]^ Another study revealed the synergistic antitumor immunity effect of radiotherapy and anti-PD-L1 antibody in non-small-cell lung cancer mouse model.^[@bibr17-1533033818793425]^ The synergistic effect of anti-PD-1 antibodies with radiotherapy in breast cancer should been explored in the future.

In recent years, studies have shown that radiotherapy could not only suppress immunity but also activate antitumor immunity and cause bystander effect.^[@bibr12-1533033818793425]^ The bystander effect can trigger systemic inflammatory reaction after local radiotherapy and promote tumor regression of distant nonradiation regional organization. In our study, compared to the healthy group, CD4^+^ and CD4^+^/CD8^+^ were obviously lower in the group with breast cancer. On the contrary, the NK expression was higher, which was consistent with the results of previous studies. Our results revealed that the radiotherapy could inhibit the immunity of the body. One week after radiotherapy, the expression of CD4^+^ was lower than that before radiotherapy, especially the RG. In addition, radiotherapy was proved to promote antitumor immunity, which mainly reflected in the following aspects, including T cell-enhancing tumor cell recognition, NK cell function activated, regulatory T cell function inhibited, apoptosis signal activated, and so on. Our research demonstrated an interesting phenomenon that CD3^+^, CD4^+^, and CD4^+^/CD8^+^ increased gradually 3 weeks after radiotherapy, which further validated the role of radiotherapy in promoting antitumor immunity.

Although this research was carefully prepared, there were some unavoidable limitations and shortcomings. First, the population of the experimental group was small, only 42 patients, and more works were necessary to confirm the results in larger samples in the future. Second, because of the single institute study, there was a potential selection bias to this study. It would be better if a multi-institute study was carried out.

Conclusions {#section12-1533033818793425}
===========

The expression PD-1 in TILs is related to immune disorder and recurrence of patients undergoing breast-preserving surgery and radiotherapy.
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